Literature DB >> 34032360

Juvenile xanthogranuloma in Noonan syndrome.

Marwan M Ali1, Amy E Gilliam2,3, Beth S Ruben2,3, William E Tidyman4,5, Katherine A Rauen4,5.   

Abstract

Noonan syndrome (NS) is one of the common RASopathies. While the clinical phenotype in NS is variable, it is typically characterized by distinctive craniofacial features, cardiac defects, reduced growth, bleeding disorders, learning issues, and an increased risk of cancer. Several different genes cause NS, all of which are involved in the Ras/mitogen-activated protein kinase (Ras/MAPK) pathway. Juvenile xanthogranuloma (JXG) is an uncommon, proliferative, self-limited cutaneous disorder that affects young individuals and may be overlooked or misdiagnosed due to its transient nature. A RASopathy that is known to be associated with JXG is neurofibromatosis type 1 (NF1). JXG in NF1 has also been reported in association with a juvenile myelomonocytic leukemia (JMML). As RASopathies, both NS and NF1 have an increased incidence of JMML. We report a 10-month-old female with NS who has a PTPN11 pathogenic variant resulting in a heterozygous SHP2 p.Y62D missense mutation. She was found to have numerous, small, yellow-pink smooth papules that were histopathologically confirmed to be JXG. In understanding the common underlying pathogenetic dysregulation of the Ras/MAPK pathway in both NS and NF1, this report suggests a possible molecular association for why NS individuals may be predisposed to JXG.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  Noonan syndrome; PTPN11; RASopathy; Ras/MAPK pathway; juvenile myelomonocytic leukemia; juvenile xanthogranuloma

Mesh:

Substances:

Year:  2021        PMID: 34032360      PMCID: PMC8446294          DOI: 10.1002/ajmg.a.62353

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.578


  26 in total

Review 1.  Juvenile myelomonocytic leukemia and Noonan syndrome.

Authors:  K Choong; M H Freedman; D Chitayat; E N Kelly; G Taylor; A Zipursky
Journal:  J Pediatr Hematol Oncol       Date:  1999 Nov-Dec       Impact factor: 1.289

Review 2.  Juvenile myelomonocytic leukemia: who's the driver at the wheel?

Authors:  Charlotte M Niemeyer; Christian Flotho
Journal:  Blood       Date:  2019-01-22       Impact factor: 22.113

Review 3.  Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1.

Authors:  D Gareth R Evans; Hector Salvador; Vivian Y Chang; Ayelet Erez; Stephan D Voss; Kami Wolfe Schneider; Hamish S Scott; Sharon E Plon; Uri Tabori
Journal:  Clin Cancer Res       Date:  2017-06-15       Impact factor: 12.531

4.  Juvenile xanthogranuloma and nevus anemicus in the diagnosis of neurofibromatosis type 1.

Authors:  Faustine Ferrari; Alice Masurel; Laurence Olivier-Faivre; Pierre Vabres
Journal:  JAMA Dermatol       Date:  2014-01       Impact factor: 10.282

5.  Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis.

Authors:  Filip Janku; Eli L Diamond; Aaron M Goodman; Vaijayanthi Kandadai Raghavan; Tamara G Barnes; Shumei Kato; Omar Abdel-Wahab; Benjamin H Durham; Funda Meric-Bernstam; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2019-04-23       Impact factor: 6.261

6.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.

Authors:  Marco Tartaglia; Charlotte M Niemeyer; Alessandra Fragale; Xiaoling Song; Jochen Buechner; Andreas Jung; Karel Hählen; Henrik Hasle; Jonathan D Licht; Bruce D Gelb
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

Review 7.  Skin manifestations of cardio-facio-cutaneous syndrome.

Authors:  L Borradori; C Blanchet-Bardon
Journal:  J Am Acad Dermatol       Date:  1993-05       Impact factor: 11.527

8.  Juvenile myelomonocytic leukaemia and Noonan syndrome.

Authors:  Marion Strullu; Aurélie Caye; Julie Lachenaud; Bruno Cassinat; Steven Gazal; Odile Fenneteau; Nathalie Pouvreau; Sabrina Pereira; Clarisse Baumann; Audrey Contet; Nicolas Sirvent; Françoise Méchinaud; Isabelle Guellec; Dalila Adjaoud; Catherine Paillard; Corinne Alberti; Martin Zenker; Christine Chomienne; Yves Bertrand; André Baruchel; Alain Verloes; Hélène Cavé
Journal:  J Med Genet       Date:  2014-08-05       Impact factor: 6.318

9.  Clinical and molecular aspects of an informative family with neurofibromatosis type 1 and Noonan phenotype.

Authors:  D A Stevenson; D H Viskochil; A F Rope; J C Carey
Journal:  Clin Genet       Date:  2006-03       Impact factor: 4.438

10.  Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.

Authors:  Benjamin H Durham; Estibaliz Lopez Rodrigo; Jennifer Picarsic; David Abramson; Veronica Rotemberg; Steven De Munck; Erwin Pannecoucke; Sydney X Lu; Alessandro Pastore; Akihide Yoshimi; Diana Mandelker; Ozge Ceyhan-Birsoy; Gary A Ulaner; Michael Walsh; Mariko Yabe; Kseniya Petrova-Drus; Maria E Arcila; Marc Ladanyi; David B Solit; Michael F Berger; David M Hyman; Mario E Lacouture; Caroline Erickson; Ruth Saganty; Michelle Ki; Ira J Dunkel; Vicente Santa-María López; Jaume Mora; Julien Haroche; Jean-Francois Emile; Olivier Decaux; Frederic Geissmann; Savvas N Savvides; Alexander Drilon; Eli L Diamond; Omar Abdel-Wahab
Journal:  Nat Med       Date:  2019-11-25       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.